Aptus Pharma logo

Aptus Pharma financials and balance sheet

BSE: 544529Pharmaceuticals & BiotechnologySmall Cap

Last close ₹491.50down ₹10.00 (1.99%)

Share price at the BSE close on 23 Oct 2026. Previous close ₹501.50.

52-week range of traded prices to 23 Oct 2026
₹48.10Low, 27 Oct 2025₹510.90High, 23 Oct 2026
Market cap
₹843 Cr2,265th largest listed
P/E
106.0
P/B
29.7
Dividend yield
Nonein the last 12 months
ROE
31.7%
Debt to equity
0.43
Volume, BSE
18,000

1 year at a glance

Standalone: the listed company alone, without its subsidiaries. ₹ crore, years to March.Aptus Pharma annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings

Operating and net margin, per cent

  • Operating margin
  • Net margin

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue47
  2. Materials and goods−21
  3. Employee costs−5.2
  4. Other expenses−13
  5. Operating profit7.4
  6. Depreciation−0.4
  7. Other income+0.1
  8. Finance costs−0.8
  9. Profit before tax6.4
  10. Tax−1.8
  11. Net profit4.6

What the company owns

  • Receivables₹19 Cr
  • Inventory₹14 Cr
  • Plant, investments and other assets₹10 Cr
  • Cash and bank₹1 Cr

What pays for it: net worth and liabilities

  • Net worth₹23 Cr
  • Owed to suppliers₹8 Cr
  • Borrowings₹7 Cr
  • Other liabilities₹5 Cr

Profit and loss

Standalone, ₹ crore, years to March.Aptus Pharma half-yearly results

₹ croreMar 2026Filed 28 Apr
Revenue from operations46.6
39.1
Materials and goods bought21.4
Employee costs5.2
Other expenses12.6
Operating profit before depreciation7.4
Operating margin16.0%
Materials, % of revenue45.9%
Employee costs, % of revenue11.2%
Other expenses, % of revenue27.0%
Depreciation and amortisation0.4
Operating profit after depreciation7.0
Other income0.1
Finance costs0.8
Profit before tax6.4
1.8
Net profit4.6
Net margin9.9%

Balance sheet

Standalone, ₹ crore, at 31 March. The last column is the half year to Sep 2026, after the latest full year: the balance sheet at its end.

₹ croreMar 2026Filed 28 AprSep 2026Half yearFiled 21 Oct
23.328.4
Share capital6.917.2
Reserves16.511.3
7.212.1
19.318.7
0.97.4
Total assets43.554.6
8.34.6
35.250.0
Net debt6.210.3
Borrowings are counted again inside the liabilities due within a year and after a year. Plant in use and plant being built are given for full years only.

Cash flow

Standalone, ₹ crore, years to March. The last column is the half year to Sep 2026, after the latest full year: the cash flow over its six months.

₹ croreMar 2026Filed 28 AprSep 2026Half year
−6.9−6.8
−5.5−5.1
−13.1−12.9
Receivables−13.1−9.9
Inventories−6.5−2.7
Payables6.91.0
Other working capital−0.4−1.4
Tax paid−1.2−1.8
Interest paid−0.10.0
Capital spending0.00.8
Free cash flow−6.9−7.6
−6.43.4
9.04.2
Dividends paid0.00.0
Shares issued13.00.0
Net change in cash−4.20.8
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only.

Per share

Standalone, ₹ per share, years to March.

₹ per shareMar 2026Filed 28 Apr
₹3.11
As stated that year₹7.78
₹3.11
₹13.61
Shareholder yield−5.4%
Market cap at the year end (₹ crore)240
Every year is restated for later splits and bonuses, so they do not break the line. The figure the company stated that year is under each line it differs from.

Ratios

Standalone, years to March.Aptus Pharma PE ratio and valuation

RatioMar 2026Filed 28 Apr
Return on equity19.8%
Return on capital employed23.1%
Cash conversion−148.5%
Interest cover8.8
Debt to equity0.31
Receivable days147
Inventory days232
Payable days139
Cash conversion cycle, days240
Working capital days169
Asset turnover1.07
Assets per rupee of net worth1.86
Sales per rupee of plant17.16
Capital spending to depreciation0.00

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
10.6%
Cash from operations against operating profit
−92.1%

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ croreLatest year
Cash from operations−6.9
Cash from investing−6.4
Cash from financing9.0
Capital spending0.0
Dividends paid0.0
Shares issued for cash13.0
Borrowings raised0.0
Borrowings repaid3.2

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2026
Effective tax ratePublished threshold 17.16 per cent27.53
Tax charged less tax paid, % of profitOur threshold 10 percentage points8.89
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
29 Jun 2026CARE Ratings Limited (opens in a new tab)Issuer RatingLong-term scaleCARE BBNew, NewStable
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.